¹**Genetic Insights into Cardiac Conduction Disorders from**

²**Genome-Wide Association Studies**

- ³**Running title**: GWAS Uncovers Genetic Links to Cardiac Conduction Disorders
-
- 4 5 Bingxun Li, PhD^{1,2*}, Hongxuan Xu, PhD^{1,2*} and Lin Wu, MD^{1,2,3#} $\frac{1}{2}$ Department of Cardiology. Peking University First Hospital. Bei
- $\frac{1}{2}$ Department of Cardiology, Peking University First Hospital, Beijing, China.
- ² State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University
- $\frac{3}{8}$ Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of
- 9 Cardiovascular Research, Southwest Medical University, Luzhou, China.
10 #Corresponding author: Lin Wu: E-mail: wuengroup@126.com: ad
- 10 #Corresponding author: Lin Wu; E-mail: wuepgroup@126.com; address: NO.8
11 Xishiku Street. Department of Cardiology. Peking University First Hospital. Beijing.
- 11 Xishiku Street, Department of Cardiology, Peking University First Hospital, Beijing,
12 China.
- 12 China.
13 *These
- ^{*}These authors contributed equally to this study.
14
-
- 15 15 Number of total words: 4,465
16 Number of words in the abstra
- 16 Number of words in the abstract: 197
17 Number of references: 40
- 17 Number of references: 40
18
-

18 ¹⁹**ABSTRACT**

BACKGROUND: Substantial data support a heritable basis for cardiac conduction
21 disorders (CCDs), but the genetic determinants and molecular mechanisms of these 21 disorders (CCDs), but the genetic determinants and molecular mechanisms of these
22 arrhythmias are poorly understood therefore we sought to identify genetic loci 22 arrhythmias are poorly understood, therefore, we sought to identify genetic loci
23 associated with CCDs. **METHODS**: We performed meta-analyses of genome-wide 23 associated with CCDs. **METHODS**: We performed meta-analyses of genome-wide
24 association studies to identify genetic loci for atrioventricular block (AVB). left 24 association studies to identify genetic loci for atrioventricular block (AVB), left
25 bundle branch block (LBBB), and right bundle branch block (RBBB) from public 25 bundle branch block (LBBB), and right bundle branch block (RBBB) from public
26 data from the UK Biobank and FinnGen consortium. We assessed evidence 26 data from the UK Biobank and FinnGen consortium. We assessed evidence
27 supporting the potential causal effects of candidate genes by analyzing relations 27 supporting the potential causal effects of candidate genes by analyzing relations
28 between associated variants and cardiac gene expression, performing 28 between associated variants and cardiac gene expression, performing ²⁹transcriptome-wide analyses, and ECG-wide phenome-wide associations for each 30 indexed SNP. **RESULTS**: Analysis comprised over 700,000 individuals for each trait.
31 We identified 10 4 and 0 significant loci for AVB (PLEKHA3 TTN FNDC3B) ³¹We identified 10, 4 and 0 significant loci for AVB (*PLEKHA3, TTN, FNDC3B,* 32 *SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5* and *TBX20*), LBBB
33 *(PPARGC1A, HAND1, TBX5, and ADAMTS5*) and RBBB. respectively. ³³(*PPARGC1A, HAND1, TBX5,* and *ADAMTS5*) and RBBB, respectively. 34 Transcriptome-wide association analysis supported an association between reduced
35 predicted cardiac expression of *SCN10A* and AVB. Phenome-wide associations 35 predicted cardiac expression of *SCN10A* and AVB. Phenome-wide associations
36 identified traits with both cardiovascular and non-cardiovascular traits with indexed 36 identified traits with both cardiovascular and non- cardiovascular traits with indexed
37 SNPs. CONCLUSIONS: Our analysis highlight gene regions associated with channel 37 SNPs. **CONCLUSIONS**: Our analysis highlight gene regions associated with channel
38 function, cardiac development, sarcomere function and energy modulation as 38 function, cardiac development, sarcomere function and energy modulation as important potential effectors of CCDs susceptibility. 39 important potential effectors of CCDs susceptibility.
40 **Key words:** Genome-Wide Association Studies.

⁴⁰**Key words**: Genome-Wide Association Studies, cardiac conduction disorders,

41 meta-analysis
42

42 43 The cardiac conduction system is crucial for propagating electrical signals that
44 coordinate cardiac contractions to maintain effective blood circulation. Disturbances 44 coordinate cardiac contractions to maintain effective blood circulation. Disturbances
45 in this system, termed cardiac conduction disorders (CCDs), can disrupt heart 45 in this system, termed cardiac conduction disorders (CCDs), can disrupt heart
46 depolarization and even result in bradycardia. Common manifestations of CCDs 46 depolarization and even result in bradycardia. Common manifestations of CCDs
47 include sick sinus syndrome (SSS), atrioventricular block (AVB), left bundle branch 47 include sick sinus syndrome (SSS), atrioventricular block (AVB), left bundle branch
48 block (LBBB), and right bundle branch block (RBBB). While significant progress has 48 block (LBBB), and right bundle branch block (RBBB). While significant progress has
49 been made in understanding the molecular mechanisms driving CCDs, current 49 been made in understanding the molecular mechanisms driving CCDs, current
50 treatments for CCDs is limited and primarily rely on implantable devices such as 50 treatments for CCDs is limited and primarily rely on implantable devices such as pacemakers¹. As a result, further research is needed to enhance our understanding and 51 pacemakers¹. As a result, further research is needed to enhance our understanding and facilitate the development of pharmacological or genetic therapies². facilitate the development of pharmacological or genetic therapies².
53 Although some CCDs can arise secondary to conditions such a

53 Although some CCDs can arise secondary to conditions such as ischemia, toxins,
54 or infections¹, genetic factors also play a significant role in their development, with 54 or infections¹, genetic factors also play a significant role in their development, with
55 studies indicating that CCDs and risk for pacemaker insertion cluster within 55 studies indicating that CCDs and risk for pacemaker insertion cluster within 56 families^{3,4}. Some researchers also suggested to include genetic testing as part of the families^{3,4}. Some researchers also suggested to include genetic testing as part of the
57. diagnostic workup in AVB patients⁵. In 2021, Thorolfsdottir et al. conducted a diagnostic workup in AVB patients⁵. In 2021, Thorolfsdottir et al. conducted a
58 genome-wide association study (GWAS) that identified several novel genetic variants 58 genome-wide association study (GWAS) that identified several novel genetic variants
59 associated with SSS, underscoring a strong genetic basis⁶. However, GWAS studies 59 associated with SSS, underscoring a strong genetic basis⁶. However, GWAS studies
60. on other maior CCDs such as AVB. LBBB. or RBBB. are not vet fully explored. To 60 on other major CCDs such as AVB, LBBB, or RBBB, are not yet fully explored. To address this gap, we performed a meta-analysis of GWAS data on AVB, LBBB, and 61 address this gap, we performed a meta-analysis of GWAS data on AVB, LBBB, and 62 RBBB to gain further insight into the pathogenesis of these disorders. 62 RBBB to gain further insight into the pathogenesis of these disorders.
63 Methods

⁶³**Methods**

⁶⁴**Study samples and meta-analysis**

65 The study was reported according to STrengthening the REporting of Genetic Association Studies (STREGA) guideline⁷. **Figure 1** depicts the study design. We Association Studies (STREGA) guideline⁷. **Figure 1** depicts the study design. We
67 included individuals with the phenotypes of interest from UK Biobank⁸ and the 67 included individuals with the phenotypes of interest from UK Biobank⁸ and the FinnGen consortium release 11^9 . Details of each cohort as well as download link FinnGen consortium release 11^9 . Details of each cohort as well as download link of GWAS summary statistics are provided in Supplemental Table 1. Because those 69 GWAS summary statistics are provided in Supplemental Table1. Because those
70 GWAS data are from two independent cohorts, there was no risk sample overlar 70 GWAS data are from two independent cohorts, there was no risk sample overlap. We
71 then conducted meta-analysis of included GWAS analyses using a fixed-effects 71 then conducted meta-analysis of included GWAS analyses using a fixed-effects
72 inverse variance weighted approach implemented in METAL¹⁰ utilizing the def Follow inverse variance weighted approach implemented in $METAL¹⁰$, utilizing the default 73 method that incorporates p-values and the direction of effect, weighted by sample si 73 method that incorporates p-values and the direction of effect, weighted by sample size.
74 To address potential population stratification bias, we applied genomic control to all 74 To address potential population stratification bias, we applied genomic control to all
75 input files. SNPs with allele frequency < 0.5% were excluded from our analysis¹¹. input files. SNPs with allele frequency $< 0.5\%$ were excluded from our analysis¹¹.
76. Because the output file of METAL doesn't include BETA and SE (standard expansion of the US

76 Because the output file of METAL doesn't include BETA and SE (standard error),
77 which are essential for further analysis, we calculated the above parameters from the 77 which are essential for further analysis, we calculated the above parameters from the 78 following formulations¹²: following formulations¹²:

$$
\text{SE} = \sqrt{\frac{1}{2 \times EAF \times (1 - EAF) \times (N + Z^2)}}
$$

 80 BETA = $Z \times SE$ 81 where EAF is effect allele frequency, N is sample size, and Z is Z score.

82 **Identification of independent locus and novel genes**
83 We used the 1000 Genomes Project phase 3 Europe

We used the 1000 Genomes Project phase 3 European (EUR) sample for linkage 2

84 disequilibrium (LD) estimation via the plinkbinr (version 0.0.0.9) and ieugwasr (version 1.0.2) packages in R (version 4.1.1). Independent locus were defined using 85 (version 1.0.2) packages in R (version 4.1.1). Independent locus were defined using a strict standard (clump window = 1Mb, $r^2 \Box = \Box 0.001$ and p-value $< 5 \times 10^{-8}$). Novel a strict standard (clump window = 1Mb, $r^2 \square = \square 0.001$ and p-value < 5×10^{-8}). Novel
87 locus, were defined as variants more than 500 kb from proviously reported ones. We 87 locus were defined as variants more than 500 kb from previously reported ones. We
88 identified the gene closest to the indexed SNP according to Ensembl within a 500 KB 88 identified the gene closest to the indexed SNP according to Ensembl within a 500 KB
89 region. CADD (Combined Annotation Dependent Depletion) scaled score for each 89 region. CADD (Combined Annotation Dependent Depletion) scaled score for each 90 SNP was looked up in the CADD v1.7 website (https://cadd.gs.washington.edu/snv)¹³. SNP was looked up in the CADD v1.7 website (https://cadd.gs.washington.edu/snv)¹³.
91. **Transcriptome-wide association study**

⁹¹**Transcriptome-wide association study**

92 We applied transcriptome-wide association study (TWAS) to identify significant
93 expression-trait associations using expression imputation from genetic data or 93 expression-trait associations using expression imputation from genetic data or summary statistics with FUSION software¹⁴. This software trains predictive models of 94 summary statistics with FUSION software¹⁴. This software trains predictive models of the genetic component of a functional or molecular phenotype and predicts and tests 95 the genetic component of a functional or molecular phenotype and predicts and tests
96 that component for association with disease using GWAS summary statistics. 96 that component for association with disease using GWAS summary statistics.
97 FUSION software was used to generate SNP weight sets from BLUP BSLMM. 97 FUSION software was used to generate SNP weight sets from BLUP, BSLMM, 98 LASSO, Elastic Net, and top SNPs utilizing genotype and expression data unless 98 LASSO, Elastic Net, and top SNPs utilizing genotype and expression data unless
99 BLUP/BSLMM was eliminated owing to sample size or convergence issues. Our goal 99 BLUP/BSLMM was eliminated owing to sample size or convergence issues. Our goal
100 was to identify associations between the phenotypes of interest and a functional 100 was to identify associations between the phenotypes of interest and a functional
101 phenotype measured only in reference data: for this analysis, we selected the GTEx 101 phenotype measured only in reference data; for this analysis, we selected the GTEx
102 version 8 heart left ventricle data¹⁵. A false discovery rate (FDR) < 0.05 was version 8 heart left ventricle data¹⁵. A false discovery rate (FDR) < 0.05 was considered significant. In addition, we conducted colocalization analysis for results 103 considered significant. In addition, we conducted colocalization analysis for results
104 with p-value ≤ 0.05 using the coloc package (version 5.1.1)¹⁶. Colocalization was 104 with p-value < 0.05 using the coloc package (version 5.1.1)¹⁶. Colocalization was
105 assessed via posterior probability for hypothesis 4 (PP.H₄), with PP.H₄ $> 80\%$ 105 assessed via posterior probability for hypothesis 4 (PP.H₄), with PP.H₄ > 80%
106 indicating significant shared causal variants. We also conduct the ioint/conditional 106 indicating significant shared causal variants. We also conduct the joint/conditional 107 tests for further verification. 107 tests for further verification.
108 **LD score regression**

¹⁰⁸**LD score regression**

We used LD Score regression $(LDSC)^{17}$ to estimate genetic correlations between
110 AVB, LBBB, and RBBB with 9 cardiovascular traits, including Brugada syndrome¹⁸. AVB, LBBB, and RBBB with 9 cardiovascular traits, including Brugada syndrome¹⁸, the heart failure (HF)¹⁹, coronary heart disease (CAD)²⁰, atrial fibrillation (AF)²¹, SSS⁶. heart failure (HF)¹⁹, coronary heart disease (CAD)²⁰, atrial fibrillation (AF)²¹, SSS⁶, 112 ORS duration (from Pan-UKBB GWAS), PR interval²², systolic blood pressure 112 QRS duration (from Pan-UKBB GWAS), PR interval²², systolic blood pressure
113 (SBP)²³ and heart rate $(HR)^{24}$ utilizing the ldscr package (version 0.1.0) in R. (SBP)²³ and heart rate $(HR)^{24}$ utilizing the ldscr package (version 0.1.0) in R.
114 European LD scores were obtained from the 1000 Genomes Project Phase 3 data for 114 European LD scores were obtained from the 1000 Genomes Project Phase 3 data for
115 HapMap2 SNPs. A p-value below 0.0019 (0.05/9/3) was considered significant for 115 HapMap2 SNPs. A p-value below 0.0019 (0.05/9/3) was considered significant for
116 LDSC. Additionally, we also analyzed the genetic associations of each clumped SNP 116 LDSC. Additionally, we also analyzed the genetic associations of each clumped SNP
117 against those risk factors. 117 against those risk factors.
118 **Phenome-wide Mendelia**

118 **Phenome-wide Mendelian randomization**
119 To perform Phenome-wide Mendelian

119 To perform Phenome-wide Mendelian randomization (PheWAS) analysis, we
120 queried the GWAS atlas database (https://atlas.ctglab.nl)²⁵, which contains 4756 queried the GWAS atlas database (https://atlas.ctglab.nl)²⁵, which contains 4756
121 GWAS summary statistics for each indexed SNP. P-values < 7.51×10^{-7} GWAS summary statistics for each indexed SNP. P-values < $7.51\,\text{m} \times 10^{-7}$
122 (0.05/4756/14) was considered as significant. For those PheWAS results fulfilled the 122 $(0.05/4756/14)$ was considered as significant. For those PheWAS results fulfilled the adjusted p-value, we also conducted colocalization analysis for further verification. 123 adjusted p-value, we also conducted colocalization analysis for further verification.
124 ECG-wide association analyses.

124 **ECG-wide association analyses.**
125 **Clumped variants of LBBB** a

125 Clumped variants of LBBB and AVB GWAS data were looked up in ECGenetics
126 (http://www.ecgenetics.org)²⁶ to explore their effect on R-R adjusted three-lead (http://www.ecgenetics.org)²⁶ to explore their effect on R-R adjusted three-lead
127 exercise electrocardiogram (ECG) morphology. The GWAS for ECG morphology exercise electrocardiogram (ECG) morphology. The GWAS for ECG morphology
3

128 consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank
129 across the complete cycle of cardiac conduction by plotting 500 association signals of 129 across the complete cycle of cardiac conduction by plotting 500 association signals of each datapoint as $-\log_{10}(p$ -values) along the time axis of one heartbeat. This analysis 130 each datapoint as $-\log_{10}(p$ -values) along the time axis of one heartbeat. This analysis aims to assess the impact of clumped LBBB and AVB variants on ECG morphology. 131 aims to assess the impact of clumped LBBB and AVB variants on ECG morphology,
132 leveraging extensive phenotyping data from the UK Biobank. By visualizing the

132 leveraging extensive phenotyping data from the UK Biobank. By visualizing the association signals as $-\log_{10}(p\text{-values})$, the study seeks to elucidate the relationship

133 association signals as $-\log_{10}(p$ -values), the study seeks to elucidate the relationship
134 between genetic variants and cardiac conduction throughout a complete heartheat. 134 between genetic variants and cardiac conduction throughout a complete heartbeat.
135 **Results**

¹³⁵**Results** ¹³⁶**Meta-analysis results and gene annotation revealed novel genes for AVB and** ¹³⁷**LBBB**

138 We conducted meta-analyses of genome-wide association results for AVB,
139 LBBB, and RBBB using data from the UK Biobank and FinnGen consortium. After 139 LBBB, and RBBB using data from the UK Biobank and FinnGen consortium. After quality control, we analyzed 19.629.603 SNPs for AVB, 19.630.647 SNPs for LBBB. 140 quality control, we analyzed 19,629,603 SNPs for AVB, 19,630,647 SNPs for LBBB, 19,631,437 SNPs for RBBB, respectively. Manhattan plots for each trait are 141 and 19,631,437 SNPs for RBBB, respectively. Manhattan plots for each trait are
142 shown in **Figure 2**, while quantile-quantile (OO) plots and lambda values 142 shown in **Figure 2**, while quantile-quantile (QQ) plots and lambda values (Supplementary Figure 1) indicated no evidence of inflation. We identified 298 143 (**Supplementary Figure 1**) indicated no evidence of inflation. We identified 298
144 SNPs for AVB, 10 for LBBB, and 1 for RBBB reached GW-significance (i.e., 144 SNPs for AVB, 10 for LBBB, and 1 for RBBB reached GW-significance (i.e., 145 p-value Γ < Γ S Γ \times Γ 10⁻⁸). After LD clumping. 10 SNPs remained for AVB (2 novel 145 p-value \Box < \Box 5 \Box × \Box 10⁻⁸). After LD clumping, 10 SNPs remained for AVB (2 novel 146 SNPs), 4 SNPs for LBBB (2 novel SNPs), and none for RBBB. Details of clumped 146 SNPs), 4 SNPs for LBBB (2 novel SNPs), and none for RBBB. Details of clumped
147 SNPs are listed in **Table 1**. We identified 10 loci for AVB and 4 loci for LBBB. 147 SNPs are listed in **Table 1**. We identified 10 loci for AVB and 4 loci for LBBB,
148 respectively, in which 2 novel loci for both AVB (rs56065557, rs7433306) and LBBB 148 respectively, in which 2 novel loci for both AVB (rs56065557, rs7433306) and LBBB
149 (rs1472095, rs9636578) were identified. 149 (rs1472095, rs9636578) were identified.
150 We then mapped potential genes ac

150 We then mapped potential genes according to distances on each chromosome for
151 indexed SNPs. We identified *PLEKHA3*, *TTN*, *FNDC3B*, *SENP2*, *SCN10A*, *RRH*, 151 indexed SNPs. We identified *PLEKHA3, TTN, FNDC3B, SENP2, SCN10A, RRH,*
152 *PPARGC1A, PKD2L2, NKX2-5, TBX20* as potential genes for AVB indexed SNPs. 152 *PPARGC1A, PKD2L2, NKX2-5, TBX20* as potential genes for AVB indexed SNPs.
153 For LBBB indexed SNPs, the potential genes included *PPARGC1A, HAND1, TBX5*, 153 For LBBB indexed SNPs, the potential genes included *PPARGC1A, HAND1, TBX5,* and *ADAMTS5*. 154 and *ADAMTS5*.
155 **TWAS and**

155 TWAS analysis indicated *SCN10A* as potential modulator for AVB
156 In the single-tissue internal validation using FUSION, of the 5, 156 In the single-tissue internal validation using FUSION, of the 5,886 genes
157 included in our genotype data showing significant cis-genetic expression in whole 157 included in our genotype data showing significant cis-genetic expression in whole
158 blood according to the GTEx dataset, 10 and 2 genes revealed significant association 158 blood according to the GTEx dataset, 10 and 2 genes revealed significant association
159 signals in the TWAS with a FDR p-value less than 0.05 for AVB and LBBB. 159 signals in the TWAS with a FDR p-value less than 0.05 for AVB and LBBB,
160 respectively, as detailed in **Supplementary Table S2** and illustrated in 160 respectively, as detailed in **Supplementary Table S2** and illustrated in 161 **Supplementary Figure 2.** No significant results were obtained for RBBB GWAS. **161 Supplementary Figure 2.** No significant results were obtained for RBBB GWAS.
162 After colocalization analysis, there were only 4 genes with PP.H4 > 0.80. In 162 After colocalization analysis, there were only 4 genes with PP.H4 > 0.80. In
163 subsequent ioint/conditional tests, we found that after conditioning on 163 subsequent joint/conditional tests, we found that after conditioning on 164 ENSG00000185313.6 (SCN10A) in the AVB GWAS data on chromosom 3. in which 164 ENSG00000185313.6 (*SCN10A*) in the AVB GWAS data on chromosom 3, in which
165 this locus goes from being genome-wide significant to non-significant after 165 this locus goes from being genome-wide significant to non-significant after conditioning on the predicted expression of ENSG00000185313.6 (SCN10A), as 166 conditioning on the predicted expression of ENSG00000185313.6 (*SCN10A*), as
167 shown in **Supplementary Figure 3.** The other 3 genes didn't have any locus with 167 shown in **Supplementary Figure 3.** The other 3 genes didn't have any locus with 168 strong enough signals to visualize due to weak effects or low statistical power. 168 strong enough signals to visualize due to weak effects or low statistical power.
169 **Genetic correlation estimates showed associations between CCD**

¹⁶⁹**Genetic correlation estimates showed associations between CCDs with** ¹⁷⁰**cardiovascular traits**

Estimates of the genetic correlation between AVB, LBBB, RBBB and 9 risk $\frac{4}{3}$

172 factors are reported in **Table 2**, in which only results with p-value < 0.0019 are listed.
173 We found that CAD and AF were closely correlated with all 3 CCDs, and HF was 173 We found that CAD and AF were closely correlated with all 3 CCDs, and HF was
174 correlated with AVB and LBBB. **Supplementary Figure 4** showed genetic 174 correlated with AVB and LBBB. **Supplementary Figure 4** showed genetic associations of clumped locus s against 9 cardiovascular traits. Notably, while AVB 175 associations of clumped locus s against 9 cardiovascular traits. Notably, while AVB
176 and PR interval exhibited a strong correlation, we did not identify a significant 176 and PR interval exhibited a strong correlation, we did not identify a significant correlation between QRS duration and LBBB/RBBB. This is likely due to the fact that 177 correlation between QRS duration and LBBB/RBBB. This is likely due to the fact that
178 PR interval and AVB are both focused on the atrioventricular node, a specific 178 PR interval and AVB are both focused on the atrioventricular node, a specific
179 conduction pathway, whereas ORS duration reflects a broader range of electrical 179 conduction pathway, whereas QRS duration reflects a broader range of electrical
180 processes within the ventricles. These processes may not always align genetically 180 processes within the ventricles. These processes may not always align genetically
181 with the more localized conduction abnormalities in LBBB and RBBB. The 181 with the more localized conduction abnormalities in LBBB and RBBB. The difference in complexity and specificity of these traits explains why a strong genetic 182 difference in complexity and specificity of these traits explains why a strong genetic
183 correlation was found in the former pair but not in the latter. Additionally, we found 183 correlation was found in the former pair but not in the latter. Additionally, we found
184 that BrS and RBBB didn't share as much strong genetic correlation as expected. This 184 that BrS and RBBB didn't share as much strong genetic correlation as expected. This
185 might indicate that although initially reported as a RBBB-like ECG change²⁷. BrS and 185 might indicate that although initially reported as a RBBB-like ECG change²⁷, BrS and RBBB are distinct diseases with different genetic background. 186 RBBB are distinct diseases with different genetic background.
187 ECG-wide associations

¹⁸⁷**ECG-wide associations**

188 The influence of indexed SNPs on ECG morphology is shown in
189 **Supplementary Figure 5.** We showed the ECG morphology phenotype plots as well **189 Supplementary Figure 5.** We showed the ECG morphology phenotype plots as well as the heatmaps for the indexed SNPs. The plots showed that the genetic ECG signature of 190 as the heatmaps for the indexed SNPs. The plots showed that the genetic ECG signature of 191 AVB clumped SNPs mainly affected the PR-segment morphology on the ECG, and LBBB 191 AVB clumped SNPs mainly affected the PR-segment morphology on the ECG, and LBBB
192 indexed SNPs mainly affected the ORS wave morphology. 192 indexed SNPs mainly affected the QRS wave morphology.
193 **PheWAS analysis**

193 **PheWAS analysis**
194 The results of

194 The results of PheWAS were present in **Supplementary Table 5**. We found that 195 apart from AF and some common ECG traits such as PR interval, HR, the indexed 195 apart from AF and some common ECG traits such as PR interval, HR, the indexed
196 SNPs in our analysis were also to be highly associated with other non-cardiac traits. 196 SNPs in our analysis were also to be highly associated with other non-cardiac traits,
197 such as estimated glomerular filtration rate, impedance measures, body 197 such as estimated glomerular filtration rate, impedance measures, body
198 anthropometric traits, etc. Because the GWAS data of ECG traits from Genevieve 198 anthropometric traits, etc. Because the GWAS data of ECG traits from Genevieve
199 Woicik et al²⁸ were not from individuals of European ancestry, we excluded those Wojcik et al^{28} were not from individuals of European ancestry, we excluded those from our results and conducted colocalization analysis. After colocalization analysis. 200 from our results and conducted colocalization analysis. After colocalization analysis,
201 we identified that some traits with high colocalization evidence (PP.H $4 > 0.80$) with 201 we identified that some traits with high colocalization evidence (PP.H4 > 0.80) with 202 indexed SNPs, and the virtualization of those results were present in **Supplementary** 202 indexed SNPs, and the virtualization of those results were present in **Supplementary** 203 **Figure 6 - 11**.

²⁰³**Figure 6 - 11**.

²⁰⁴**Discussion** 205 In this meta-analysis of GWAS for 3 clinically important CCDs using 2
206 independent cohorts, we identified 10 and 2 genome-wide disease susceptibility loci 206 independent cohorts, we identified 10 and 2 genome-wide disease susceptibility loci
207 for AVB and LBBB, respectively, including 2 novel locus were identified for each 207 for AVB and LBBB, respectively, including 2 novel locus were identified for each 208 GWAS. Our findings primarily highlighted genes involved in ion channel function. 208 GWAS. Our findings primarily highlighted genes involved in ion channel function,
209 sarcomere function, cardiac development and energy modulation, supporting and 209 sarcomere function, cardiac development and energy modulation, supporting and 210 extending previous findings suggesting an genetic basis of CCDs and underscore the 210 extending previous findings suggesting an genetic basis of CCDs and underscore the
211 complex genetic architecture underlying these disorders³⁻⁶. Additionally, they suggest complex genetic architecture underlying these disorders³⁻⁶. Additionally, they suggest potential pathways for future research and therapeutic targeting. 212 potential pathways for future research and therapeutic targeting.
213 Most susceptibility locus are associated with genes the

213 Most susceptibility locus are associated with genes that affect cardiac ion
214 channels, such as *SCN10A, TBX20* and *TBX5*. Variations in *SCN10A* have been 214 channels, such as *SCN10A, TBX20* and *TBX5*. Variations in *SCN10A* have been
215 identified to influence cardiac conduction and PR interval²⁹. TWAS analysis also identified to influence cardiac conduction and PR interval²⁹. TWAS analysis also 5 216 suggested *SCN10A* as an important regulator for AVB. The T-box proteins are also
217 essential for cardiac conduction system morphogenesis and activation or repression of 217 essential for cardiac conduction system morphogenesis and activation or repression of 218 kev regulatory genes³⁰. These genes primarily impact the cardiac conduction system. key regulatory genes³⁰. These genes primarily impact the cardiac conduction system,
219. potentially leading to conduction delays. 219 potentially leading to conduction delays.
220 We also observed susceptibility locu-

220 We also observed susceptibility locus for both AVB and LBBB that mapped to 221 *PPARGC1A* (also known as $PGC-I\alpha$), an important mitochondrial energy metabolism *PPARGC1A* (also known as $PGC-I\alpha$), an important mitochondrial energy metabolism
222 factor, suggesting that *PPARGC1A* may be an important modulator for cardiac 222 factor, suggesting that *PPARGC1A* may be an important modulator for cardiac
223 conduction. *PPARGC1A* is involved in the regulation of oxidative phosphorylation 223 conduction. *PPARGC1A* is involved in the regulation of oxidative phosphorylation
224 and mitochondrial biogenesis, processes critical for maintaining cellular energy 224 and mitochondrial biogenesis, processes critical for maintaining cellular energy homeostasis, and is closely associated with cardiovascular diseases³¹. Disruption of 225 homeostasis, and is closely associated with cardiovascular diseases³¹. Disruption of mitochondrial function can lead to altered ion channel expression and disrupted Ca² 226 mitochondrial function can lead to altered ion channel expression and disrupted Ca^{2} homeostasis, which in turn increases susceptibility to arrhythmias in both atrial³² and homeostasis, which in turn increases susceptibility to arrhythmias in both atrial³² and
228 ventricular tissues³³ in mice with *PPARGCIA* deficiency. ventricular tissues³³ in mice with *PPARGC1A* deficiency.
229 Our results further implicate the cardiac sarcomer

229 Our results further implicate the cardiac sarcomere for AVB and LBBB. We
230 identified a susceptibility locus for AVB at *PLEKHA3*, located just downstream of 230 identified a susceptibility locus for AVB at *PLEKHA3*, located just downstream of 231 TTN. TTN encodes the large cardiac structural protein titin, which is essential for the 231 *TTN*. TTN encodes the large cardiac structural protein titin, which is essential for the 232 assembly and function of vertebrate striated muscles. By providing connections at the 232 assembly and function of vertebrate striated muscles. By providing connections at the
233 level of individual microfilaments, titin helps maintain the delicate balance of forces 233 level of individual microfilaments, titin helps maintain the delicate balance of forces
234 between the two halves of the sarcomere. Variants in TTN are among the most 234 between the two halves of the sarcomere. Variants in TTN are among the most 235 common inheritable risk factors for dilated cardiomyopathy³⁴ and have been common inheritable risk factors for dilated cardiomyopathy³⁴ and have been
236 associated with early-onset AF^{35} . A recent research also identified TTN as an 236 associated with early-onset AF^{35} . A recent research also identified TTN as an important susceptibility locus paroxysmal supraventricular arrhythmia related to 237 important susceptibility locus paroxysmal supraventricular arrhythmia related to 238 accessory pathways³⁶ 238 accessory pathways³⁶.
239 We also found s

239 We also found some genes associated with cardiac development. The Small
240 Ubiquitin-like Modifier (SUMO) modification, implicated in various cellular 240 Ubiquitin-like Modifier (SUMO) modification, implicated in various cellular processes including protein trafficking, transcriptional regulation, protein stability, 241 processes including protein trafficking, transcriptional regulation, protein stability,
242 cell death, and survival, is important to maintain physiological function. 242 cell death, and survival, is important to maintain physiological function.
243 SUMOvlation of several ion channels such as SCN5A to affect conduction³⁷. We SUMOylation of several ion channels such as SCN5A to affect conduction³⁷. We found SENP2, a key member of the SENPs family that regulates SUMOylation, in 244 found SENP2, a key member of the SENPs family that regulates SUMOylation, in 245 AVB susceptibility locus. The downstream target of SENP2 including NKX2-5³⁸. 245 AVB susceptibility locus. The downstream target of SENP2 including NKX2- 5^{38} , another identified gene in AVB GWAS data, which functions in heart formation and 246 another identified gene in AVB GWAS data, which functions in heart formation and
247 development. Mutations in this gene cause atrial septal defect with atrioventricular 247 development. Mutations in this gene cause atrial septal defect with atrioventricular
248 conduction defect, and also tetralogy of Fallot, which are both heart malformation 248 conduction defect, and also tetralogy of Fallot, which are both heart malformation
249 diseases³⁹. Another gene with potential influence on cardiac development is HAND1 diseases³⁹. Another gene with potential influence on cardiac development is HAND1 as one of LBBB susceptibility locus. HAND1 is a key transcription factor involved in 250 as one of LBBB susceptibility locus. HAND1 is a key transcription factor involved in
251 early cardiogenesis. It is one of two closely related family members known as the 251 early cardiogenesis. It is one of two closely related family members known as the 252 HAND proteins, which are asymmetrically expressed in the developing ventricular 252 HAND proteins, which are asymmetrically expressed in the developing ventricular
253 chambers and play an essential role in cardiac morphogenesis. Acting in a 253 chambers and play an essential role in cardiac morphogenesis. Acting in a
254 complementary manner, these proteins are crucial for the formation of the right 254 complementary manner, these proteins are crucial for the formation of the right
255 ventricle and the aortic arch arteries, implicating them as significant mediators of 255 ventricle and the aortic arch arteries, implicating them as significant mediators of 256 congenital heart disease⁴⁰. 256 congenital heart disease⁴⁰.
257 We also observed so

257 We also observed some genes, such as RRH, FNDC3B, and ADAMTS5, that 258 have not been extensively studied in the context of cardiovascular function. 258 have not been extensively studied in the context of cardiovascular function.
259 Additionally, our PheWAS analysis revealed that some indexed SNPs were closely Additionally, our PheWAS analysis revealed that some indexed SNPs were closely 6

260 associated with non-cardiac traits, including estimated glomerular filtration rate
261 (eGFR). These findings suggest a broader role for these genes and SNPs beyond 261 (eGFR). These findings suggest a broader role for these genes and SNPs beyond
262 traditional cardiovascular implications, highlighting the need for further investigation 262 traditional cardiovascular implications, highlighting the need for further investigation
263 into their functions. 263 into their functions.
264 Limitations

²⁶⁴**Limitations**

265 We recognize several limitations in our analysis. Firstly, the genetic data
266 primarily derives from individuals of European ancestry, which may restrict the 266 primarily derives from individuals of European ancestry, which may restrict the 267 applicability of our findings to other ethnic groups. Secondly, despite a total sample 267 applicability of our findings to other ethnic groups. Secondly, despite a total sample
268 size exceeding 700.000, we did not retain SNPs in the RBBB GWAS data after 268 size exceeding 700,000, we did not retain SNPs in the RBBB GWAS data after clumping. Further studies are necessary to address this gap. 269 clumping. Further studies are necessary to address this gap.
270 **Conclusion**

²⁷⁰**Conclusion**

271 In this meta-analysis of GWAS including 2 independent cohorts and over
272 700.000 European individuals, we identified 10 and 2 previously reported 272 700,000 European individuals, we identified 10 and 2 previously reported
273 genome-wide associations with AVB and LBBB, respectively, and 2 novel 273 genome-wide associations with AVB and LBBB, respectively, and 2 novel
274 associations for each GWAS. Our findings primarily implicate genes involved in ion 274 associations for each GWAS. Our findings primarily implicate genes involved in ion
275 channel function, cardiac development, sarcomere function and energy modulation as 275 channel function, cardiac development, sarcomere function and energy modulation as
276 important potential effectors of risk for AVB and LBBB. 276 important potential effectors of risk for AVB and LBBB.
277 **Data availability**

²⁷⁷**Data availability**

278 All the data used were acquired from publicly available dataset according to the
279 PubMed ID or links provided in **Stable 1**. No restricted dataset was used in this study. 279 PubMed ID or links provided in **Stable 1**. No restricted dataset was used in this study.
280 The summary statistics didn't contain any personal information. For code supporting 280 The summary statistics didn't contain any personal information. For code supporting this manuscript, please refer to https://github.com/bingxunli/block. 281 this manuscript, please refer to https://github.com/bingxunli/block.
282 **Authors' contributions**

²⁸²**Authors' contributions**

283 BX Li and HX Xu (first author): Conceptualization, Methodology, Software, 284 Investigation, Formal Analysis, Writing and Original Draft: Y Chen and YY Lin: Data 284 Investigation, Formal Analysis, Writing and Original Draft; Y Chen and YY Lin: Data
285 Curation, Writing and Original Draft: L Wu (Corresponding Author): Writing, Review 285 Curation, Writing and Original Draft; L Wu (Corresponding Author): Writing, Review
286 and Editing, Funding acquisition. All authors have reviewed the manuscript and 286 and Editing, Funding acquisition. All authors have reviewed the manuscript and approved its submission in current version. 287 approved its submission in current version.
288 Ethics approval

²⁸⁸**Ethics approval**

289 Not applicable
290 **Consent to particin** ²⁹⁰**Consent to participate**

-
- 291 Not applicable
292 **Consent for public** ²⁹²**Consent for publication**

293 Not applicable
294 Acknowledgments

²⁹⁴**Acknowledgments**

295 We would like to extend our deepest appreciation to the providers of open data
296 and all the individuals who participated in the studies. 296 and all the individuals who participated in the studies.
297 **Funding**

²⁹⁷**Funding**

298 This work is funded by National Natural Science Foundation of China (Project 299 approval number: 82370312). 299 approval number: 82370312).
300 **References**

³⁰⁰**References**

301 1 Kusumoto, F. M. et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and

-
- 302 Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of
303 the American College of Cardiology/American Heart Association Task Force on
- 304 Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 140,
- 305 e382-e482, doi:10.1161/cir.0000000000000628 (2019).
- 306 2 Li, T., Marashly, Q., Kim, J. A., Li, N. & Chelu, M. G. Cardiac conduction diseases:
- 307 **206** 2 understanding the molecular mechanisms to uncover targets for future treatments.
- 308 understanding the molecular mechanisms to uncover targets for future treatments.
308 final expert opinion on therapeutic targets 28, 385-400, 308 *Expert opinion on therapeutic targets* 28, 385-400,
309 doi:10.1080/14728222.2024.2351501 (2024).
-
- 310 3 Kaess, B. M. et al. Familial Clustering of Cardiac Conduction Defects and Pacemaker 310 3 Kaess, B. M. et al. Familial Clustering of Cardiac Conduction Defects and Pacemaker
311 Sinsertion. *Circulation. Arrhythmia and electrophysiology* 12, e007150, 311 Insertion. *Circulation. Arrhythmia and electrophysiology* **12**, e007150,
312 doi:10.1161/circep.119.007150 (2019).
- 313 4 Dyssekilde, J. R. et al. Familial risk of atrioventricular block in first-degree relatives.

314 Heart 108, 1194-1199, doi:10.1136/heartinl-2021-320411 %J Heart (2022).

- 315 5 Resdal Dyssekilde, J. et al. Diagnostic Yield of Genetic Testing in Young Patients With
- 316 **5 Atrioventricular Block of Unknown Cause**. Journal of the American Heart Association
- 317 **11, e025643, doi:10.1161/jaha. 121.025643 (2022).**
- 318 6 Thorolfsdottir, R. B. et al. Genetic insight into sick sinus syndrome. *European heart* 319 *journal* 42, 1959-1971, doi:10.1093/eurheartj/ehaa1108 (2021).
- 320 7 Little, J. et al. STrengthening the REporting of Genetic Association Studies (STREGA):
- 321 an extension of the STROBE statement. $PLoS$ medicine 6, e22, 321 an extension of the STROBE statement. *PLoS medicine* 6, e22,
322 doi:10.1371/journal.pmed.1000022 (2009).
- 323 8 Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. $\frac{323}{8}$

- Anture 562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
325 9 Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
- 326 9000 population. Nature 613, 508-518, doi:10.1038/s41586-022-05473-8 (2023).
- 327 10 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of 328 10 genomewide association scans. Bioinformatics (Oxford, England) 26, 2190-2191,
- 329 doi:10.1093/bioinformatics/btq340 (2010).
- 330 11 Rasooly, D. et al. Genome-wide association analysis and Mendelian randomization
- 331 100 11 proteomics identify drug targets for heart failure. Nature communications 14, 3826,
- 332 doi:10.1038/s41467-023-39253-3 (2023).
- 333 12 Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts
- 334 complex trait gene targets. Nature genetics 48, 481-487, doi: 10.1038/ng. 3538 (2016).
- 335 13 Schubach, M., Maass, T., Nazaretyan, L., Röner, S. & Kircher, M. CADD v1.7: using
- 336 136 protein language models, regulatory CNNs and other nucleotide-level scores to
- 337 protein improve genome-wide variant predictions. Nucleic acids research 52, D1143-d1154, 111 improve genome-wide variant predictions. Nucleic acids research 62, D1145-d1154,
338 doi:10.1093/nar/gkad989 (2024).
-
- 138 doi:10.1093/nar/gkad989 (2024).
14 Gusev, A. *et al*. Integrative approaches for large-scale transcriptome-wide association 340 studies. Nature genetics 48, 245-252, doi:10.1038/ng.3506 (2016).
- 341 15 The GTEx Consortium atlas of genetic regulatory effects across human tissues. 342 Science (New York, N.Y.) 369, 1318-1330, doi:10.1126/science.aaz1776 (2020).
- 343 16 Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic
- 344 344 association studies using summary statistics. PLoS genetics 10, e1004383,
- 345 **doi:10.1371/journal.pgen. 1004383 (2014)**. 345 doi:10.1371/journal.pgen.1004383 (2014).
8

- 346 17 Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from 348 doi:10.1038/ng.3211 (2015).
- 198 doi:10.1038/ng.3211 (2015).
18 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk
- 350 18 Ioci and highlight a new mechanism of sodium channel regulation in disease 351 susceptibility. Nature genetics 54, 232-239, doi:10.1038/s41588-021-01007-6 (2022).
-
- 352 19 Shah, S. et al. Genome-wide association and Mendelian randomisation analysis
- 353 **19. et al. Encycloptival ensurest** and the pathogenesis of heart failure. *Nature communications* 11, 163,
- 354 doi:10.1038/s41467-019-13690-5 (2020).
- 355 20 Aragam, K. G. et al. Discovery and systematic characterization of risk variants and 356 356 356 356 genes for coronary artery disease in over a million participants. Nature genetics 54,

357 1803-1815, doi: 10.1038/s41588-022-01233-6 (2022).

- 358 21 Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into atrial 359 **21 Ibrillation biology**. *Nature genetics* 50, 1234-1239, doi:10.1038/s41588-018-0171-3 359 fibrillation biology. *Nature genetics* 60, 1234-1239, doi:10.1038/s41588-018-0171-3
360 (2018).
-
- 360 (2018).
361 22 Ntalla, I*. et al.* Multi-ancestry GWAS of the electrocardiographic PR interval identifies 362 202 loci underlying cardiac conduction. Nature communications 11, 2542, 363 doi:10.1038/s41467-020-15706-x (2020).
- 364 23 Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci 365 255 associated with blood pressure traits. Nature genetics 50, 1412-1425, 366 doi:10.1038/s41588-018-0205-x (2018).
- 367 24 van de Vegte, Y. J. et al. Genetic insights into resting heart rate and its role in 367 24 van de vegte, Y. O. *G. al.* Genetic insights lifts resting heart rate and its role in

- 368 cardiovascular disease. *Nature communications* 14, 4646,
369 doi:10.1038/s41467-023-39521-2(2023).
-
- 370 25 Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in 371 complex traits. Nature genetics 51, 1339-1348, doi:10.1038/s41588-019-0481-0 372 complex traits. *Nature genetics* 51, 1339-1348, doi:10.1038/s41588-019-0481-0
372 (2019).
-
- 172 (2019).
373 26 Verweij, N. *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* 11, 374 229-238 e225, doi:10.1016/j.cels.2020.08.005 (2020).
- 375 27 Brugada, J., Brugada, R. & Brugada, P. Right bundle-branch block and ST-segment
- 376 **276** elevation in leads V1 through V3: a marker for sudden death in patients without 377 elevation in leads V1 through V3: a marker for sudden death in patients marker
377 demonstrable structural heart disease. *Circulation* 97, 457-460, 377 demonstrable structural heart disease. Circ*ulation* 97, 457-460,
378 doi:10.1161/01.cir.97.5.457 (1998).
- 178 doi:10.1161/01.cir.97.5.457 (1998).
179 − 28 − Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for 380 complex traits. Nature 570, 514-518, doi:10.1038/s41586-019-1310-4 (2019).
- 381 29 Chambers, J. C. et al. Genetic variation in SCN10A influences cardiac conduction.

382 **Nature genetics 42**, 149-152, doi:10.1038/ng 516 (2010).

383 30 van Eif, V. W. W., Devalla, H. D., Boink, G. J. J. & Christoffels, V. M. Transcriptional

384 regulation of the cardiac conduction system. Nature reviews. Cardiology 15, 617-630,

- 385 doi:10.1038/s41569-018-0031-y (2018).
- 386 31 Qian, L. et al. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1)
- 387 **387** family in physiological and pathophysiological process and diseases. *Signal* 388 framsduction and targeted therapy 9, 50, doi:10.1038/s41392-024-01756-w (2024).
- 389 32 Chadda, K. R. et al. Gene and Protein Expression Profile of Selected Molecular 389 32 Chadda, K. R. et al. Gene and Protein Expression Profile of Selected Molecular

- 390 Targets Mediating Electrophysiological Function in Pgc-1α Deficient Murine Atria.
391 *International journal of molecular sciences* 19, doi:10.3390/ijms19113450 (2018).
-
- 392 33 Saadeh, K. et al. Molecular basis of ventricular arrhythmogenicity in a Pgc-1 α deficient
- 393 393 murine model. *Molecular genetics and metabolism reports* 27, 100753,
- 394 doi:10.1016/j.ymgmr. 2021. 100753 (2021).
- 395 34 Herman, D. S. et al. Truncations of titin causing dilated cardiomyopathy. The New 396 *England journal of medicine* 366, 619-628, doi:10.1056/NEJMoa1110186 (2012).
- 397 35 Choi, S. H. et al. Association Between Titin Loss-of-Function Variants and Early-Onset
- 398 Atrial Fibrillation. Jama 320, 2354-2364, doi:10.1001/jama 2018.18179 (2018).
- 399 36 Weng, L. C. et al. Meta-Analysis of Genome-Wide Association Studies Reveals
- 400 36 Genetic Mechanisms of Supraventricular Arrhythmias. Circulation. Genomic and 401 *precision medicine* 17, e004320, doi:10.1161/circgen.123.004320 (2024).
- 402 37 Yoon, J. Y. et al. SUMOylation of the cardiac sodium channel $Na(V)1.5$ modifies 402 37 Yoon, J. Y. *L. al.* Solvicylation of the cardiac sodium channel Na(V)1.5 modifies
403 **Inward** current and cardiac excitability. *Heart rhythm* 20, 1548-1557, 403 inward current and cardiac excitability. Heart rhythm 20, 1548-1557,
- 405 38 Wang, J., Zhang, H., Iyer, D., Feng, X. H. & Schwartz, R. J. Regulation of cardiac 406 **388 Specific nkx2.5 gene activity by small ubiquitin-like modifier**. The Journal of biological
- 407 chemistry 283, 23235-23243, doi:10.1074/jbc.M709748200 (2008).
- 408 39 Cao, C. et al. Nkx2.5: a crucial regulator of cardiac development, regeneration and 409 Cao, C. *et al. NKX2.5*: a crucial regulator of cardiac development, regeneration and
409 diseases. *Frontiers in cardiovascular medicine* 10, 1270951, 409 diseases. *Frontiers in cardiovascular medicine* 1**0**, 1270951,
410 doi:10.3389/fcvm.2023.1270951 (2023).
- 411 40 Riley, P., Anson-Cartwright, L. & Cross, J. C. The Hand1 bHLH transcription factor is 412

- 412 essential for placentation and cardiac morphogenesis. Nature generies 18, 271-275,
413 doi:10.1038/ng0398-271 (1998). 113 doi:10.1038.ng000 21 (1998).
414
415
-
-
-
-
-
-
-
-
-

-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- 446 Figure 1 Schematic diagram.
447 AVB, atrioventricular block;

- 448 block; SNP, Single-Nucleotide Polymorphism; LD, linkage disequilibrium; LDSC, 449 LD score regression; PheWAS, phenome-wide association study; TWAS,
- 449 LD score regression; PheWAS, phenome-wide association study; TWAS, transcriptome-wide association study
- 450 transcriptome-wide association study
451
-
- 452 Figure 2. Manhattan plots showing GWAS meta-analysis of. A) AVB; B) LBBB; and
453 C) RBBB. Those plots shows the $-\log_{10}(p\text{-value})$ of association for each SNP from
- C) RBBB. Those plots shows the $-\log_{10}(p\text{-value})$ of association for each SNP from 13

⁴⁴⁷ AVB, atrioventricular block; LBBB, left bundle branch block; RBBB, bundle branch
448 block; SNP, Single-Nucleotide Polymorphism; LD, linkage disequilibrium; LDSC,

-
- 454 the GWAS meta-analysis plotted on the y-axis against genomic position on the x-axis.
455 The gray line corresponds to the genome-wide significance threshold $(5\Box \times \Box 10^{-8})$. The gray line corresponds to the genome-wide significance threshold ($5\Box \times \Box 10^{-8}$).
456 Novel locus identified genes are highlighted in bold.
- Novel locus identified genes are highlighted in bold.

Table 1. Locus reported for AVB and LBBB in the meta-analysis of UK Biobank and FinnGene GWAS datasets. Findings were identified using fixed effects inverse-variance weighted meta-analysis. The chromosomal position is based on GRCh37/hg19 reference. Gene names are italicized. Novel locus (i.e., distance > 500kB from previous locus) are shown in bold. CHR, chromosome; POS, base pair location; NEA, non-effect allele; EA, effect allele; EAF, effect allele frequency; SE, standard error; CADD, Combined Annotation Dependent Depletion

463 Table 2. LDSC analysis results showing genetic correlations between CCDs and related cardiovascular traits. Here only significant results were present. AVB, 464 related cardiovascular traits. Here only significant results were present. AVB, atrioventricular block; LBBB, left bundle branch block; RBBB, right bundle branch 465 atrioventricular block; LBBB, left bundle branch block; RBBB, right bundle branch
466 block; AF, atrial fibrillation; CAD, coronary heart disease; HF, heart failure; SSS, sick 466 block; AF, atrial fibrillation; CAD, coronary heart disease; HF, heart failure; SSS, sick sinus syndrome; SBP, systolic blood pressure; r_g , genetic correlation; SE, standard 467 sinus syndrome; SBP, systolic blood pressure; *r*_g, genetic correlation; SE, standard error. error.

